Abstract: Eyelid malignancies are common ocular adnexal malignancies, which can not only affect the patient's vision and appearance, but also have a great threat to the patient's life. In recent years, based on the studies of the Hedgehog pathway, epidermal growth factor receptor (EGFR) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mediated pathways and the immune checkpoint pathway, some targeted agents have shown certain efficacy and safety against eyelid malignancies, such as basal cell carcinoma, cutaneous squamous cell carcinoma, malignant melanoma, and Merkel cell carcinoma. Targeted therapy and immunotherapy provide additional options for patients with eyelid malignancies that recur after surgical resection, progress after systemic therapy, locally advanced or metastatic. Combined therapies have a higher response rate and longer survival than monotherapy. In the future, with the discovery of more downstream targets and better combined therapies, more treatment options will be available for eyelid malignancies.

Key words: eyelid malignancies, molecular targeted therapy, immunotherapy